Obesity is highly prevalent in Western populations and is considered a risk factor for the development of renal impairment. Interventions that reduce the tissue burden of advanced glycation end-products (AGEs) have shown promise in stemming the progression of chronic disease. Here we tested if treatments that lower tissue AGE burden in patients and mice would improve obesity-related renal dysfunction. Overweight and obese individuals (body mass index (BMI) 26-39 kg/m 2 ) were recruited to a randomized, crossover clinical trial involving 2 weeks each on a low-and a high-AGE-containing diet. Renal function and an inflammatory profile (monocyte chemoattractant protein-1 (MCP-1) and macrophage migration inhibitory factor (MIF)) were improved following the low-AGE diet. Mechanisms of advanced glycation-related renal damage were investigated in a mouse model of obesity using the AGE-lowering pharmaceutical, alagebrium, and mice in which the receptor for AGE (RAGE) was deleted. Obesity, resulting from a diet high in both fat and AGE, caused renal impairment; however, treatment of the RAGE knockout mice with alagebrium improved urinary albumin excretion, creatinine clearance, the inflammatory profile, and renal oxidative stress. Alagebrium treatment, however, resulted in decreased weight gain and improved glycemic control compared with wild-type mice on a high-fat Western diet. Thus, targeted reduction of the advanced glycation pathway improved renal function in obesity.
Obesity is highly prevalent in Western populations and is considered a risk factor for the development of renal impairment. Interventions that reduce the tissue burden of advanced glycation end-products (AGEs) have shown promise in stemming the progression of chronic disease. Here we tested if treatments that lower tissue AGE burden in patients and mice would improve obesity-related renal dysfunction. Overweight and obese individuals (body mass index (BMI) 26-39 kg/m 2 ) were recruited to a randomized, crossover clinical trial involving 2 weeks each on a low-and a high-AGE-containing diet. Renal function and an inflammatory profile (monocyte chemoattractant protein-1 (MCP-1) and macrophage migration inhibitory factor (MIF)) were improved following the low-AGE diet. Mechanisms of advanced glycation-related renal damage were investigated in a mouse model of obesity using the AGE-lowering pharmaceutical, alagebrium, and mice in which the receptor for AGE (RAGE) was deleted. Obesity, resulting from a diet high in both fat and AGE, caused renal impairment; however, treatment of the RAGE knockout mice with alagebrium improved urinary albumin excretion, creatinine clearance, the inflammatory profile, and renal oxidative stress. Alagebrium treatment, however, resulted in decreased weight gain and improved glycemic control compared with wild-type mice on a high-fat Western diet. Thus, targeted reduction of the advanced glycation pathway improved renal function in obesity. Obesity is an important risk factor for type 2 diabetes and its subsequent complications including renal and cardiovascular diseases. Between 2010 and 2030, it is estimated that worldwide numbers of diabetes cases will increase by 54%. 1 As such, the International Diabetes Federation has proposed lifestyle changes as a cost-effective method of preventing or delaying the onset of type 2 diabetes, 2 which would likely extend to manifestations of obesity such as an increased risk of chronic kidney disease. 3 Current figures show that 30-50% of individuals with diabetes will develop nephropathy. 4 It is well known that certain lifestyle choices such as diets high in saturated fat and processed foods contribute to obesity and the development of type 2 diabetes, although the exact mechanisms involved have not been fully defined. Dietary fat and processed foods are extremely high in a group of sugar modifications known as advanced glycation endproducts (AGEs). These molecules improve taste, reduce food spoilage, and promote longer shelf life. Excessive dietary intake of AGEs has recently been shown to contribute to renal 5 and cardiovascular 6 diseases and the development of type 2 diabetes, especially in the context of a high-fat diet in animal models. 7 Once in circulation, [8] [9] [10] dietary AGEs may cause inflammation and free oxygen radical production by modulation of specific receptors, including the receptor for AGE (RAGE). Interestingly, the kidney is the main organ responsible for the removal of AGEs from the bloodstream.
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This high exposure of the kidney to AGEs is likely to make the organ particularly susceptible to AGE-mediated damage. The potential for reduction in dietary AGEs to improve renal function in nonobese, renal failure patients has been demonstrated after a 4-week low-AGE diet that reduced serum creatinine concentrations by 30-40%. 9 This study investigated the effects of lowering the accumulation of AGEs or interrupting RAGE downstream signaling pathways using a model of obesity-related renal disease in mice. The efficacy of a reducing dietary AGE intake to improve renal function in obese humans was also examined.
RESULTS

Clinical study
The baseline characteristics of the 11 participants are shown in Table 1 . Although diets were isocaloric and matched for macronutrient content, on a 9 MJ/day diet, individuals were calculated to consume 14,090 kU N-carboxymethyllysine (CML) on the high-AGE diet and 3302 kU CML on the low-AGE diet. There was no effect of the dietary interventions on body weight, body mass index (BMI), or adiposity, which remained elevated (Table 2) .
Renal function and inflammatory makers. Urinary albumin/creatinine ratios were significantly better following the low AGE dietary period in obese individuals (low-vs high-AGE diet: P ¼ 0.02, Figure 1a) . Plasma cystatin C levels were elevated following consumption of a high-AGE diet for 2 weeks (low vs high: P ¼ 0.02, Figure 1b ). Plasma CML concentrations following high AGE consumption declined (low vs high: P ¼ 0.01, Figure 1c ), whereas urinary CML concentrations increased following consumption of the high-AGE diet (low vs high: P ¼ 0.03, Figure 1d ). The high-AGE diet increased urinary 8-isoprostanes (low vs high: P ¼ 0.02, Figure 1e ). Plasma monocyte chemoattractant protein-1 (MCP-1), also known as chemokine (C-C motif) ligand 2 (CCL2), was increased as a result of high AGE dietary consumption (low vs high: P ¼ 0.04, Figure 1f) . Conversely, however, plasma macrophage migration inhibitory factor (MIF) significantly declined after consumption of the high-AGE diet (low vs high: P ¼ 0.04, Figure 1g ). There were no significant effects of the order in which the diets were consumed on any of the parameters, when these data were analyzed via repeated measures analysis of variance with order as a between-subject factor. There were no differences in other circulating cytokines and transcription factors including endogenous secreted form of RAGE, soluble RAGE (sRAGE), nuclear factor-kB, interleukin-6, and high-sensitivity C-reactive protein between diets (data not shown).
Murine study
Biochemical and metabolic parameters. Both wild-type (WT) and RAGE-/-mice consuming the Western-style diet, high in AGEs and fat content, were obese by week 16 (DBW ;  Table 3 ), with significant increases in epididymal and omental adipose depots (Table 3) . Increases in body weight and fat deposition after the Western diet were prevented using the AGE-lowering therapy, alagebrium (ALA, Table 3 ). Kidney size was unaffected by dietary consumption of a western-style diet (Table 3) . Fasting plasma glucose and insulin concentrations were increased in obese mice following the consumption of the western diet in both WT and RAGE-/-mouse strains (Table 3) , and the parameters were significantly improved in the mice treated with ALA.
Renal functional parameters. Renal function was assessed by albumin excretion rate and creatinine clearance. Obese WT mice consuming the Western-style diet had albuminuria (Figure 2a) , which was reduced in obese RAGE-/-mice fed a Western diet but not with ALA. Creatinine clearance was elevated in obese WT mice and significantly improved by ALA (Figure 2b ). Furthermore, a western diet did not induce hyperfiltration in RAGE-/-mice ( Figure 2b ). All obese mice had lower plasma CML concentrations (Figure 2c ) despite consuming more dietary AGEs than lean low-AGE-fed mice (Figure 2d ). Urinary CML excretion was below detectable limits (5.6 nmol/mol lysine) in all mice. Also of interest was that obese WT (16.8 ± 11.2 kJ/day) and RAGE-/-mice (29.7 ± 6.9 kJ/day) consumed less kilojoules per day than both lean low-AGE-fed mice (50.3 ± 3.4 kJ/day; Po0.05 vs obese WT) or obese mice treated with ALA (34.9±9.4 kJ/day; Po0.05 vs obese WT).
Concentrations of the AGE CML in renal cortices were significantly increased in obese and obese ALA-treated animals but not in obese RAGE knockout mice when measured via enzyme-linked immunosorbent assay (ELISA; Figure 2e ). Immunohistochemistry confirmed that there were increases in CML in renal cortices taken from obese mice that were not seen in lean low-AGE-fed mice (Figure 2f) .
RAGE protein expression and inflammation. Membranous RAGE protein concentrations in renal cortices taken from obese WT mice were significantly higher than those in lean mice consuming a low-AGE diet (Figure 3a ). This parameter was not affected by treatment with ALA ( Figure 3a) . Circulating levels of sRAGE, measured via ELISA, tended to be higher in obese mice, although they were significantly lower after ALA therapy (lean low AGE (216.6±65.98 pg/ml) vs obese (352.2±172.4 pg/ml) RAGE, Po0.05; obese vs obese ALA (152.2 ± 55.67 pg/ml RAGE, Po0.05). As expected, there was no expression of membranous or soluble RAGE protein detected in RAGE-/-mice (data not shown). Renal MCP-1 levels were significantly lower in obese ALA-treated animals and obese RAGE-/-mice ( Figure 3b ) when compared with untreated obese WT mice. Plasma MIF concentrations in mice were decreased with obesity and significantly increased by ALA treatment or in obese RAGE-/-mice ( Figure 3c ). Kidney MIF levels were increased in obese mice, which were not affected by ALA treatment; however, deletion of RAGE significantly decreased renal MIF concentrations ( Figure 3d ). Collagen IV deposition in glomerular cortices was not significantly different among treatment groups (Figure 3e and f). 
DISCUSSION
This study has provided evidence that intervention using diets low in AGE content may attenuate renal changes seen with obesity. Although our current human study did not encourage weight loss in obese participants because of matching of caloric intake and the short duration of dietary intervention (2 weeks), we were able to demonstrate that altering dietary AGE content alone is sufficient to improve inflammatory profiles and early renal disease. These findings are consistent with a previous study of patients with advanced end-stage renal disease. 12 To complement these findings, we performed studies in mice to further define potential mechanisms linking the AGE/RAGE axis to renal functional changes in the context of obesity. Indeed, our studies in obese mice highlighted that interfering with the AGE/RAGE axis by either preventing AGE tissue accumulation with the AGE-lowering therapy, ALA, or via RAGE deletion in RAGE-/-mice is protective against obesity-related renal dysfunction. These findings are consistent with previous evidence that AGE formation is important in the pathogenesis of other chronic kidney diseases. [13] [14] [15] [16] [17] The increases in the expression of the proinflammatory protein RAGE in kidney cortices taken from obese mice, and its contributory role to obesity-related renal dysfunction in this model, was further suggested in obese RAGE-/-mice who had better renal function and less inflammation. Elevations in the circulating concentrations of sRAGE were also seen in obese mice, consistent with findings in type 2 diabetic individuals with nephropathy who are generally obese. 18, 19 Although sRAGE was not changed after a low-AGE diet in our human study, this was most likely because of the short duration of the dietary intervention. It is possible that a longer dietary duration would have ultimately led to lower circulating sRAGE concentrations. This hypothesis is supported by the improved inflammatory profile seen with consumption of a low-AGE diet as reflected by decreased MCP-1 and MIF concentrations which in the context of previous studies which have associated increases in sRAGE with systemic inflammation. [19] [20] [21] We have also demonstrated for the first time that total AGE burden is likely a combination of circulating, tissue and excreted AGE concentrations in obesity. Furthermore this can be modulated via alteration of diet or treatment with therapies, as was the case in our murine study. Previous other studies have reported that circulating AGE concentrations may be an indication of renal disease progression as they showed increases. 22 As a result of our findings, we therefore heed caution at this becoming a gold standard marker.
Given the findings of this study and the previously reported roles of RAGE, it is possible that inflammation plays a role in modulating the changes seen in this study. In both obese humans and mice, there was evidence of low-grade inflammation, which was enhanced by consumption of a high-AGE diet. This increased plasma MCP-1 and lowered MIF concentrations, attenuated by interrupting the AGE/ RAGE axis, either by lowering the tissue AGE burden using dietary means, the AGE-lowering therapy ALA, or by deletion of RAGE. Activation of RAGE has already been reported to be crucial for macrophage recruitment, as highlighted by its role in host-pathogen defense. 23 Therefore, it is likely that RAGE activation as a result of AGE stimulation is a modulator of MCP-1 and MIF secretion in this study. However, obesityrelated changes in circulating insulin concentrations seen in both humans and mice may also be indirectly modulating the expression of MIF (localized in the pancreatic islets 24 ) and MCP-1 (from white adipose tissue 21, 25 ) that are known to affect insulin secretion and action, respectively.
AGEs and RAGE are also known to contribute to renal dysfunction via excess generation of reactive oxygen species. [26] [27] [28] High-AGE diets in both obese humans and mice appear to influence oxidative stress as reflected by increases in urinary isoprostanes and renal superoxide production. This pro-oxidant effect of AGEs is further suggested by the findings in obese mice that received ALA that appeared to have less oxidative stress. RAGE deficiency did not improve obesity-related increases in urinary isoprostane excretion, which was interesting given that this group also had a lack of effect on adiposity and obesity-related abnormalities in glycemic control. This suggests that the benefits afforded by low-AGE diets and ALA on oxidative stress may be partly independent of RAGE. This is not totally surprising as AGEs can interact with other receptors in addition to RAGE, and ALA is likely to have additive actions that may be relevant including a modest effect as an antioxidant. 15, 29 In conclusion, this study suggests that a low-AGE diet has an impact on modulating renal function in healthy obese individuals. Studies in murine models suggest that the mechanism responsible for AGE effects on renal function is likely to involve its receptor RAGE and include improvements in inflammation, oxidative stress, and glycemic control.
MATERIALS AND METHODS Clinical study
Participant selection. This study was approved by the Alfred Hospital Ethics Committee and conducted according to the Declaration of Helsinki Principles. All individuals gave written informed consent before commencement of the study. Participants were males, aged between 18 and 50 years with stable body weight (weight change o5 kg in last year), BMI X25 kg/m 2 , normal glucose tolerance (by oral glucose tolerance test), and healthy according to medical history, examination, and basic blood screening. Exclusion criteria included morbid obesity (BMI X40 kg/m 2 ), current smoking habit, high alcohol use or a positive urine drug screening test, any medication taken within 1 month before commencing the study, presence of acute inflammation (by history, physical, or laboratory examination), or highly unusual dietary habits or vegan diet.
Clinical study design and anthropometric and metabolic measurements. In all, 11 healthy overweight males participated in a clinical dietary intervention study involving 2 weeks each of low-and high-AGE diet separated by a 4-week wash-out period. Participants kept a 3-day diet record (two weekdays and one weekend day) based on household measures. Nutrient content was analyzed with SERVE (SERVE Nutrition Systems, St Ives, NSW, Australia), based on Australian Food Composition tables plus US data for food AGE content. 30 Results guided food selection and indicated the approximate habitual AGE intake. A menu of carefully matched alternative food choices (Table 4) , each similar in macronutrients and total kilojoules but differing in total AGE content, were prepared for each meal of the day, including snacks and beverages, according to previously described guidelines. 30 All foodstuffs for the low-and high-AGE diets were provided to the individuals, in addition to instructions for storage and preparation of meals (method, temperature, and duration of cooking). Participants were instructed to eat to appetite, and maintain normal physical activity as measured by IPAQ (International Physical Activity Questionnaire) 31 and by accelerometer (Respirotics Minimitter, Bend, OR). Participants had a 6-week run-in period of the high-AGE diet as this was generally similar to their normal dietary habits, and were then randomized to either the low-AGE or high-AGE diet for 2 weeks. At the commencement and conclusion of each 2-week dietary test period, body weight, waist-hip ratio, and adiposity by four-point bioimpedence analysis (Body Composition Analyser, Model BC-418MA; Tanita, Middlesex, UK) were measured and BMI calculated. A 24-h urine collection and fasting plasma sample were taken at the commencement of the study and further spot urine and fasting plasma samples were taken before and after dietary interventions. Fasting plasma samples were analyzed for glucose (Radiometer, Copenhagen, Denmark) and insulin via ELISA.
Renal function. Before and after each dietary period, spot urines and plasma samples were taken to assess serum creatinine and urinary albumin/creatinine ratios. Creatinine clearance was estimated via the Cockcroft-Gault formula, 32 and albumin excretion rates assayed in 24 h urine collections at baseline.
CML indirect ELISA. CML was measured in human serum (1:8000) and urine samples (1:4) before and after each diet at their respective dilutions, using an in-house indirect CML ELISA that has been previously described. 33 CML was also measured in mouse chow, murine plasma, urine, and renal cortices using the previously described methods. 15, 29 Immunohistochemistry. Immunohistochemistry analysis for CML and collagen IV was performed on paraffin-embedded neutral buffered formalin-fixed murine kidneys as previously described. 34 Cystatin C, MIF, and MCP-1 ELISAs. Cystatin C was measured in human plasma samples according to the manufacture's instructions in a 1:1000 dilution (Human Cystatin C; BioVendor, 12 While Australian foods may differ in AGE content, all foods prepared for the high-AGE diet were subjected to a high level of browning. Cola is a rich source of methylglyoxal in addition to CML.
Mordice, Czech Republic). MIF was measured in human plasma (R&D Systems, Minneapolis, MN) and murine plasma and renal cytosolic fractions (USCN Life, Wuhan, China) according to the manufacturer's guidelines. MCP-1 was assayed in human plasma (R&D Systems) and murine renal cortex cytosolic protein fractions (Raybiotech, Norcross, GA).
Murine study
Study design. Male WT, C57BL/6J (WT), and RAGE-deficient mice (RAGE-/-) 35 on a C57BL/6J background were housed in a temperature-controlled environment with a 12 h light-dark cycle (Alfred Medical Research and Education (AMREP) Precinct Animal Centre, Melbourne, Australia). At 8 weeks of age, groups of C57BL/6J mice (n ¼ 10/group) were randomized to either (1) a high-AGE, high-fat, Western diet (obese; SF05-031, Specialty Feeds, Perth, Australia, baked for 1 h at 160 1C, 101.9 nmol/mol lysine of CML per 100 mg) (2) a high-AGE, high-fat Western diet plus the AGE-lowering therapy ALA (obese ALA; 1 mg/kg/day oral gavage; Synvista Therapeutics, Montvale, NJ), or (3) a low-AGE standard fat diet (lean; AIN-93G, Specialty Feeds, unbaked; 20.9 nmol/mol lysine of CML per 100 mg). Food intake and water access was ad libitum with diets matched for vitamin and amino-acid content. However, 40% of total energy in the Western diet was derived from animal fat (Ghee; 210 g/kg) versus 16% of total energy in the low-AGE diet. One further group of RAGE-/-mice consuming the Western diet were also studied (n ¼ 10; obese RAGE-/-). All animal studies were performed in accordance with the guidelines from the AMREP Animal Ethics Committee and the National Health and Medical Research Council of Australia.
Murine physiological and biochemical parameters. Body weight, fasting plasma glucose, and fasting plasma insulin were measured at 16 weeks as previously described. 36 The 24 h metabolic caging to collect urine and measure food and water intake was performed at weeks 8 and 16 of the study. Albumin excretion rate was assessed using a mouse albumin ELISA kit according to the manufacturer's instructions (Bethyl Laboratories, Montgomery, TX). Creatinine clearance was determined following HPLC (Agilent HP1100 system, Hewlett Packard, Nuremberg, Germany) measurement of creatinine content in timed plasma and urine samples as previously described and in accordance with AMDCC (Animal Models of Diabetic Complications Consortium) guidelines. 37 Frozen renal cortex was processed via ultracentrifugation as previously described 15 in order to generate membrane, cytosol, and nuclear protein fractions.
Urinary isoprostane concentrations. As a noninvasive measure of oxidative stress, 8-isoprostane F 2 was measured in 24 h human urine samples collected before and after each diet by competitive ELISA (Oxford Biomedical Research, Oxford, MI). Human urine samples were assayed neat and the assay was conducted as per the manufacturer's instructions. Murine urine samples were also analyzed neat for 8-isoprostane, according to the manufacturer's instructions (8-isporostane enzyme immunoassay; Cayman Chemical, Ann Arbor, MI).
Superoxide production. Renal superoxide was measured in fresh murine renal cortical tissue as previously described via chemiluminescence of lucigenin. 38, 39 Renal RAGE expression. Murine renal cytosolic protein fractions were assayed for RAGE protein using an ELISA specific for mouse (R&D Systems). Unknown values were calculated relative to a four-parameter logistic standard curve generated using the GraphPad Prism program (GraphPad Prism, San Diego, CA). All assays were run according to the manufacturer's instructions.
Statistical analyses. Human data were expressed as mean ± s.e.m. unless otherwise stated and were analyzed using paired Student's t-test analysis. Urinary albumin/creatinine values were nonparametric and were therefore logarithmically transformed before analysis. Order effect of the diets was analyzed via repeated measures analysis of variance with order as a between-subject factor. Human statistical analyses were performed using SPSS (SPSS Statistics 17.0, IBM, Somers, NY).
Murine study analyses were performed by one-way analysis of variance followed by Tukey's post hoc analysis (GraphPad Prism, 5.2). Mouse data are presented as mean ± s.d. Mouse albuminuria data were not normally distributed and were therefore logarithmically transformed before analysis. A Po0.05 was considered to be statistically significant. 
